Literature DB >> 17482832

Adverse reactions to contrast media: an analysis from spontaneous reporting data.

Paola Cutroneo1, Giovanni Polimeni, Roberto Curcuruto, Gioacchino Calapai, Achille P Caputi.   

Abstract

Diagnostic contrast media (CM) are a widely used class of drugs with poor information regarding their safety. Nevertheless, epidemiological studies showed that CM cause adverse reactions commonly considered unpreventable and unavoidable. Because spontaneous reporting is a valuable methodology for better defining the safety profile of drugs after their approval, we analyzed the spontaneous reports of suspected adverse reactions attributed to CM sent to the Sicilian Regional Centre for the Spontaneous Reporting of Adverse Drug Reactions (ADRs) during the period from 1996 to 2006, with the aim to identify their most important features. One hundred ADR reports out of 3471 involved CM (2.9%); 29 reports were serious, including 1 fatal case. Skin, respiratory system and gastrointestinal tract were most frequently affected sites. The majority of reports described hypersensitivity reactions with immediate onset. Iopromide (52.5%), iopamidol (13.9%) and iomeprol (11.9%) were the drugs with the highest number of reports. Case reports collected by the Sicilian Regional Centre showed that CM adverse reactions are not common or not commonly signalled; however, in agreement with previous published reports, analysis of data suggests that they are generally allergic-like reactions. Further investigations are needed within post-marketing surveillance to identify and prevent the consequences of CM adverse reactions and interactions. Awareness about CM safety should be promoted among all healthcare professionals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482832     DOI: 10.1016/j.phrs.2007.03.003

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  9 in total

1.  Evaluation of adverse reactions to contrast media in the hospital.

Authors:  E-J Kyung; J-H Ryu; E-Y Kim
Journal:  Br J Radiol       Date:  2013-11-04       Impact factor: 3.039

2.  Comparison of concurrent complications of CKD by 2 risk categorization systems.

Authors:  Lesley A Inker; Marcello Tonelli; Brenda R Hemmelgarn; Emily B Levitan; Paul Muntner
Journal:  Am J Kidney Dis       Date:  2011-11-23       Impact factor: 8.860

3.  Ligands and Signaling of Mas-Related G Protein-Coupled Receptor-X2 in Mast Cell Activation.

Authors:  Yan-Ni Mi; Na-Na Ping; Yong-Xiao Cao
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

4.  Contrast Media Adverse Drug Reactions in Highly Polluted Environment.

Authors:  Natalia Sauer; Wojciech Szlasa; Laura Jonderko; Krystyna Głowacka; Katarzyna Karłowicz-Bodalska; Anna Wiela-Hojeńska
Journal:  Int J Environ Res Public Health       Date:  2022-06-09       Impact factor: 4.614

5.  Dimethyl 5-nitro-isophthalate.

Authors:  Min-Hao Xie; Pei Zou; Yong-Jun He; Ya-Ling Liu; Biao Huang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-08-09

6.  Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India.

Authors:  Vivekanandan Kalaiselvan; Surbhi Sharma; Gyanendra Nath Singh
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

7.  Micro soft tissues visualization based on x-ray phase-contrast imaging.

Authors:  Lu Zhang; Shuqian Luo
Journal:  Open Med Inform J       Date:  2011-07-27

8.  Differences between Drug-Induced and Contrast Media-Induced Adverse Reactions Based on Spontaneously Reported Adverse Drug Reactions.

Authors:  JiHyeon Ryu; HeeYoung Lee; JinUk Suh; MyungSuk Yang; WonKu Kang; EunYoung Kim
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

9.  Contrast Agents and Observing Patient Safety Programs in Radiology Departments in Kermanshah Province Hospitals in West of Iran.

Authors:  Fatemhe Amiri; Mohammad Rasoul Tohidnia; Somayeh Haydarizadi; Rasool Azmoonfar
Journal:  Acta Inform Med       Date:  2018
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.